Will HEXO Stock Get High in June 2021?

Does HEXO’s leadership position in several segments make it a good long-term buy?

| More on:
edit Jars of marijuana

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn moresdf

Canadian pot producers have underperformed the broader markets in the last two years. The majority of domestic marijuana companies have been impacted by massive losses and cash burn, which has led them to raise capital and boost liquidity while diluting shareholder wealth. HEXO (TSX:HEXO)(NYSE:HEXO) is one such stock on the TSX; it is down 80% from record highs.

Let’s see if this Canadian pot heavyweight is a good contrarian bet or a stock to avoid right now.

HEXO stock was up 10% on Friday

Shares of HEXO gained 10% on May 28 after the company announced the acquisition of Redecan for $925 million. Redecan is Canada’s largest privately owned LP (licensed producer), and HEXO disclosed it will pay $400 million in cash and $525 million in stock to complete the acquisition.

According to HEXO, this deal will allow it to lead the Canadian recreational cannabis market. The company is optimistic it will also benefit from “improved future financial performance and [a greater] potential to generate cash flow” after this acquisition. While investors cheered this news, it seems HEXO is betting big on the chance to generate a positive cash flow.

The purchase of Redecan will also mark HEXO’s third acquisition in 2021. In February, it acquired Zenabis Global for $235 million in an all-stock deal. Earlier this month, it bought 48North Cannabis for $41 million.

By the time HEXO and Zenabis complete the merger, the combined entity is forecast to deliver over $150 million in sales and generate $20 million in cost synergies in the next 12 months.

HEXO stock is up 82% year to date and is well poised to gain market share in Canada’s cannabis segment. It already leads the cannabis-infused beverage space given its joint venture with Molson Coors.

A look at recent quarterly results

In the fiscal second quarter of 2021, HEXO’s sales were up 94% year over year at $32.8 million. It sold 11,419 kilograms of dried cannabis in Q2 compared with just 6,579 kilograms in the prior-year period. HEXO also claimed the company is getting better in terms of predicting demand-supply dynamics, as it harvested an additional 6,000 kilograms of cannabis in Q2 compared to its total sales. In the prior-year period, it harvested an additional 16,000 kilograms.

Further, HEXO increased its gross margin by 600 basis points to 40% in Q2. This improvement in gross margin helped HEXO reported a positive EBITDA of $202,000 compared to a loss of $419,000 in the year-ago period. HEXO’s management explained the company finally achieved a positive EBITDA after seven consecutive quarters of improving margins. In Q2, the pot producer decreased operating expenses by a staggering 91% year over year.

HEXO should continue to enjoy stellar top-line growth driven by the opening of retail stores in major Canadian provinces. At the end of April, Ontario had 613 open legal cannabis stores while Alberta had 600 stores. In June 2020, Ontario had fewer than 100 stores while Alberta had just 483 stores.

HEXO might turn profitable in fiscal 2023

Analysts expect HEXO to increase sales by 77% to $143 million in fiscal 2021 and by 60% to $228 million in 2022. This will allow HEXO to improve loss per share from $7.08 in fiscal 2020 to $0.05 in fiscal 2022. However, there is a good chance for these estimates to increase once the above-mentioned acquisitions are over.

HEXO stock is trading at a forward price-to-sales multiple of 7.6, which might seem steep. Alternatively, its leadership position, improving profitability, and focus on acquisitions make it a good bet for investors with a high-risk appetite.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

The Motley Fool recommends HEXO. and HEXO. Fool contributor Aditya Raghunath has no position in any of the stocks mentioned.

More on Cannabis Stocks

Cannabis smoke
Cannabis Stocks

Canopy Growth Stock: Is Now a Good Time to Invest?

The road ahead is highly uncertain for Canopy Growth, as the stock is plagued with losses and seemingly unsurmountable industry…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

TLRY Stock: Should You Invest Now?

TLRY is a Canadian cannabis stock which is trading 91% below record highs. Let's see if you should own TLRY…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Is Tilray Stock a Buy in February 2023?

Despite the volatile cannabis sector, Tilray could be a superb buy for long-term investors.

Read more »

Young woman sat at laptop by a window
Cannabis Stocks

Is SNDL Stock a Buy in February 2023?

SNDL is a beaten-down cannabis stock. While its revenue growth is exceptional, a weak balance sheet has driven stock prices…

Read more »

A cannabis plant grows.
Cannabis Stocks

TLRY Stock: Here’s What’s Coming in 2023

Tilray Inc. (TSX:TLRY) is geared up for big growth this decade and looks like one of the top cannabis stocks…

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

Canopy Growth Stock: Here’s What’s Coming in 2023

Canopy Growth stock has made a lot of new moves in the last few months, but where is the company…

Read more »

A cannabis plant grows.
Cannabis Stocks

Better Cannabis Buy: Canopy Growth Stock or Tilray?

Only two TSX weed stocks can deliver substantial returns in the highly anticipated growth of the global cannabis market.

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Is Tilray Stock a Buy in January 2023?

Tilray stock has lost 50% of its value in the last 12 months, in line with its peers.

Read more »